Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors

NCT06796907 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06796907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06796907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors
Lead sponsor
GlaxoSmithKline
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 4, 2025
Completion date
October 10, 2028
Enrollment
305 (estimated)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

tumours, gynecological